Pipeline overview

COMPASS development programmes

COMPASS-owned and sponsored

Programme	Discovery	Preclinical	Phase I	Phase II	Phase III	Approved
COMP360 for TRD						
COMP360 for PTSD						
Prodrug programme						
Discovery Center						

Investigator-initiated studies

Signal-generating exploratory studies looking at indications in areas of unmet need with COMP360

- COMPASS has pending patent applications that include the indications listed
- COMPASS owns or has a license to new IP generated
- Studies may provide signals that we can explore further and bring into our development pipeline

Indication	Institution	CMPS financed	
MDD in cancer patients	Aquilino Cancer Center	✓	*Complete*
MDD	University of Zurich		
Chronic cluster headache	University of Copenhagen		
Severe TRD	Sheppard Pratt	✓	
Bipolar disorder II	Sheppard Pratt	✓	
Body dysmorphic disorder	Columbia University	✓	
Anorexia nervosa	UC San Diego	✓	
Suicidal ideation	Sheppard Pratt	✓	
Autism	King's College London	✓	

Note: TRD = treatment-resistant depression, PTSD = post-traumatic stress disorder, MDD = major depressive disorder. We do not sponsor investigator-initiated studies, some of which use their own protocols and study design. We encourage the open publication of all associated findings from any study or trial using COMP360

CONFIDENTIAL | © COMPASS Pathways 2020